Skip to content

H.R. 1525 · 119th Congress (2025–2027)

Protecting Life from Chemical Abortions Act

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers.

The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention.

The bill also generally prohibits the declaration of a public health emergency with respect to abortions.

Show official title

To prohibit the use or declaration of a public health emergency with respect to abortion, and for other purposes.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 1525’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Kevin Hern (R-OK-1)
Cosponsors
25 cosponsors

20 original · 5 later

25 R

  1. Rep. Robert B. Aderholt (R-AL-4)· Original · Feb 24, 2025
  2. Rep. Lauren Boebert (R-CO-4)· Original · Feb 24, 2025
  3. Rep. Mike Bost (R-IL-12)· Original · Feb 24, 2025
  4. Rep. James R. Baird (R-IN-4)· Original · Feb 24, 2025
  5. Rep. Dan Crenshaw (R-TX-2)· Original · Feb 24, 2025
  6. Rep. Warren Davidson (R-OH-8)· Original · Feb 24, 2025
  7. Rep. Troy Downing (R-MT-2)· Original · Feb 24, 2025
  8. Rep. Randy Feenstra (R-IA-4)· Original · Feb 24, 2025
  9. Rep. Mark E. Green (R-TN-7)· Original · Feb 24, 2025
  10. Rep. Michael Guest (R-MS-3)· Original · Feb 24, 2025
  11. Rep. Pat Harrigan (R-NC-10)· Original · Feb 24, 2025
  12. Rep. Doug LaMalfa (R-CA-1)· Original · Feb 24, 2025
  13. Rep. John R. Moolenaar (R-MI-2)· Original · Feb 24, 2025
  14. Rep. Mary E. Miller (R-IL-15)· Original · Feb 24, 2025
  15. Rep. Dan Newhouse (R-WA-4)· Original · Feb 24, 2025
  16. Rep. John H. Rutherford (R-FL-5)· Original · Feb 24, 2025
  17. Rep. John W. Rose (R-TN-6)· Original · Feb 24, 2025
  18. Rep. Keith Self (R-TX-3)· Original · Feb 24, 2025
  19. Rep. Daniel Webster (R-FL-11)· Original · Feb 24, 2025
  20. Rep. Randy K. Weber, Sr. (R-TX-14)· Original · Feb 24, 2025
  21. Rep. Ashley Hinson (R-IA-2)· Later · May 19, 2025
  22. Rep. Ben Cline (R-VA-6)· Later · Jun 4, 2025
  23. Rep. Andy Biggs (R-AZ-5)· Later · Sep 9, 2025
  24. Rep. Julia Letlow (R-LA-5)· Later · Feb 25, 2026
  25. Rep. Eric Burlison (R-MO-7)· Later · Jun 10, 2026
Policy area
Health
Subjects
  • Abortion
  • Drug safety, medical device, and laboratory regulation
  • Drug therapy
  • Government information and archives
  • Health information and medical records
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Feb 24, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Protecting Life from Chemical Abortions Act

    Display title, Short title · Introduced in House

  2. To prohibit the use or declaration of a public health emergency with respect to abortion, and for other purposes.

    Official title · Introduced in House